
Windlas Biotech Limited



Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407



Ref No. WBL/SE/2022-2023

May 24, 2022

To Listing / Compliance Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001

To Listing / Compliance Department National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051

NSE SYMBOL: WINDLAS

BSE CODE: 543329

Dear Sir/ Madam.

Sub: Press Release

Please find attached herewith the Press Release given by the Company.

This is for your information and dissemination to the members of the exchange.

Thanking you,

Yours faithfully,

For Windlas Biotech Limited

Augandy

Ananta Narayan Panda Company Secretary & Compliance Officer

Encl: as above



www.windlas.com

Press Release

Windlas Biotech Limited receives EU-GMP certificate

Tuesday, 24th May 2022, Gurugram: Windlas Biotech Limited, one of the leading domestic pharmaceutical formulations contract development and manufacturing organization ("CDMO") industry in India, has now received the certificate of European Union Good Manufacturing Practices (EU-GMP) by the National Institute of Pharmacy and Nutrition, Hungary for the Plant-IV situated at Dehradun. The company had undergone an inspection from 11th to 13th April 2022.

Commenting on this Mr. Hitesh Windlass, Managing Director – Windlas Biotech said, "We are delighted to receive the EU-GMP certificate for our Plant-IV. The company had received a GMP certificate from SAHPRA (South African Health Products Regulatory Authority) for the same plant in April 2022. These successive positive outcomes from the reputed regulatory authorities strongly reflect our core philosophy – adhering to the highest standards of quality, maintaining robust systems and strong execution capabilities. Successful completion of these audits will allow the company to expand its geographic presence in those respective markets."

About Windlas Biotech Limited

The company (Windlas) is one of the leading domestic pharmaceutical formulations contract development and manufacturing organization ("CDMO") industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, the Company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices ("GMP") with a focus on improved safety, efficacy and cost.



Safe Harbor

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information please contact:



Windlas Biotech Limited CIN: U74899UR2001PLC033407

Ms. Komal Gupta Email: Komal@windlasbiotech.com

Contact no.: +91 124 2821034



Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285

Mr. Jigar Kavaiya / Mr. Chinmay Madgulkar Email: jigar.kavaiya@sgapl.net / chinmay.m@sgapl.net

Contact no.: +91 9920602034 / +91 9860088296